Sorrento, Servier in Exclusive Anti-PD-1 License Agreement

Sorrento Therapeutics, Inc. and Servier have entered a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento’s fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110.
 
Sorrento’s G-MAB library platform was used to identify and generate STI-A1110, which targets PD-1, one of the key targets in immuno-oncology therapies. Servier has an exclusive worldwide license to STI-A1110 mAb covering all indications including hematological and solid tumor cancers. Servier also obtains full rights to develop and commercialize the products.
 
Sorrento will receive €25 million upfront and is eligible to receive development milestones, and as much as €710 million based on commercial sales milestones and royalties.
 
“We are excited about partnering on our anti-PD-1 immune checkpoint antibody with Servier, which is recognized for its scientific excellency and as a pioneer in CAR-T therapies. This agreement represents validation for Sorrento’s antibody technologies and R&D capabilities,” said Dr. Henry Ji, president and chief executive officer of Sorrento. “This also further establishes Sorrento as a notable immuno-oncology company with a comprehensive portfolio of clinical stage and preclinical immunotherapies. We look forward to working closely with the Servier team and growing this global partnership.”
 
“We have tested STI-A1110 in preclinical studies conducted at Servier and we believe that, used in combination with several products from our portfolio, it will lead to the development of new treatments for hematological as well as solid tumor cancers,” added Dr. Jean-Pierre Abastado, Director of the Oncology Innovation Therapeutic Pole for Servier.